Lupin Ltd has started financial year 2026-27 on a strong note, with robust growth across its major markets helping the pharmaceutical company deliver a 16% year-on-year rise in consolidated profit after tax (PAT) for the June quarter.
The company reported a consolidated PAT of ₹1,417 crore for Q1 FY27, compared with ₹1,221 crore in the same quarter last year. Revenue from operations climbed 32% year-on-year to ₹8,277 crore from ₹6,268 crore a year earlier. The numbers underline the continuing strength of Lupin’s business across the US, India and other international markets.
The quarterly performance was also stronger at the operating level. Lupin’s EBITDA rose 43% year-on-year to ₹2,580 crore, while the EBITDA margin improved to 31.4%, compared with 29.3% in Q1 FY26. The improvement in margins points to stronger operating leverage and a favourable product and geographic mix.
Lupin’s gross profit increased 39.5% to ₹6,128 crore during the quarter, with gross margin expanding to 74.6% from 71.3% a year earlier. Profit before tax rose 42.5% to ₹2,017 crore.
The company’s performance was led particularly by its international business. US sales, Lupin’s largest market, increased 42.9% year-on-year to ₹3,435 crore. The US business accounted for about 42% of the company’s global sales during the quarter. In dollar terms, US sales rose to $366 million from $282 million in the year-ago period.
The strong US performance was supported by new product launches and regulatory approvals. Lupin received six abbreviated new drug application (ANDA) approvals from the US Food and Drug Administration during the quarter and launched three products in the US. The company now has 149 generic products in the US market.
India remained another important growth engine. Lupin’s India sales increased 13.9% year-on-year to ₹2,380 crore, accounting for about 29% of global sales. Sales from India’s formulations business grew 15.1% during the quarter, while the company launched seven brands across different therapeutic areas.
The company also recorded notable growth beyond its two largest markets. Sales in other developed markets rose 48.3% to ₹1,149 crore, while emerging-market sales jumped 51.7% to ₹990 crore. Together, these markets helped broaden Lupin’s revenue base and reduce dependence on any single geography.
Formulations remained the main contributor to the company’s growth. Total formulations sales increased 34.3% year-on-year to ₹7,954 crore. Global active pharmaceutical ingredient (API) sales grew at a more modest 8.5% to ₹264 crore.
Lupin’s first-quarter numbers also reflect continued investment in research and innovation. The company spent ₹608 crore on research and development during the quarter, equivalent to 7.4% of sales. Its cumulative ANDA filings with the US FDA stood at 429 as of June 30, 2026, with 350 approvals received so far. The company also has 50 First-to-File filings, including 21 exclusive opportunities.
The balance sheet remained relatively comfortable. Lupin reported net debt of negative ₹2,831 crore as of June 30, effectively indicating a net cash position. Capital expenditure during the quarter stood at ₹279 crore, while operating working capital was ₹8,260 crore.
Lupin Managing Director Nilesh Gupta said the company had made a strong start to FY27, driven by growth across key markets and continued improvement in profitability. He highlighted execution, operational excellence and investments in technology and innovation as important factors supporting the company’s longer-term growth.
The latest Lupin Q1 FY27 results therefore present a picture of a pharmaceutical business benefiting from broad-based demand rather than relying solely on one market. The US continues to provide significant momentum, while India, emerging markets and other developed markets are adding to the growth story.
For investors tracking the Indian pharmaceutical sector, the key takeaway is the combination of strong revenue growth and expanding operating profitability. With Lupin continuing to strengthen its generic portfolio, invest in R&D and expand its presence across global markets, the first-quarter performance provides a positive opening to FY27.
However, sustaining this momentum through the rest of the financial year will depend on the company’s ability to maintain US growth, execute new product launches, manage costs and convert its expanding product pipeline into commercial opportunities.
For now, Lupin’s Q1 FY27 performance shows a company entering the new financial year with healthy growth across markets, stronger operating margins and continued investment in its future portfolio.